RPT-Amneal Pharmaceuticals' Q2 revenue misses estimates
Overview
Amneal Q2 2025 net revenue rises 3% but misses analyst expectations, per LSEG data
Adjusted EBITDA for Q2 2025 increases 13% to $184 mln, reflecting higher revenue and gross margin
Co raises full year 2025 guidance, citing strong product uptake and FDA approval
Outlook
Amneal raises 2025 adjusted EBITDA guidance to $665 mln - $685 mln
Company increases 2025 adjusted EPS forecast to $0.70 - $0.75
Amneal boosts 2025 operating cash flow outlook to $275 mln - $305 mln
Company expects 2025 net revenue between $3.0 bln and $3.1 bln
Result Drivers
SPECIALTY SEGMENT - Specialty net revenue rose 23% due to strong performance of branded products like CREXONT and RYTARY
DEBT REFINANCING - Successful debt refinancing reduced interest costs and extended maturities, improving financial position
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $724.51 mln | $744.60 mln (4 Analysts) |
Q2 Net Income |
| $35.61 mln |
|
Q2 Gross Profit |
| $286.25 mln |
|
Q2 Operating Income |
| $111.37 mln |
|
Q2 Pretax Profit |
| $51.71 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $12.00, about 33.7% above its August 4 closing price of $7.96
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago
Press Release: ID:nGNX7xhvwb
